Three technology companies are working together to integrate their technologies into the NIH-funded International Diabetes Closed Loop (IDCL) Trial. The companies include Tandem Diabetes Care® (TNDM) www.tandemdiabetes.com manufacturer of touchscreen insulin pumps, Dexcom Inc., www.dexcom.com a leader in continuous glucose monitoring, and TypeZero Technologies LLC., www.typezero.com a digital health and personalized medicine company.
A Tandem insulin pump and Dexcom G5 sensor will be included as part of a blood glucose control system to combine both devices with a smartphone running TypeZero’s inControl closed loop algorithm. The system is able to predict high and low blood sugar levels and adjusts insulin delivery accordingly throughout the day.
Tandem and Dexcom anticipate adding a Dexcom G6 sensor-integrated t:slim X2 Pump that will be able to incorporate inControl’s algorithms directly into the pump’s touchscreen interface to the IDCL Trial. The trial is projected to enroll 240 adults with type 1 diabetes soon and the study is expected to last 2.5 years.
“The IDCL Trial is designed as a pivotal trial of a closed-loop control-to-range system and includes seven institutions in the U.S and three in Europe led by the University of Virginia,” said Boris Kovatchev, PhD, Director of the Center for Diabetes Technology at the University of Virginia and Principle Investigator of the IDCL Trial.